GSK Examines Zika Vaccine Capabilities As Fears Of Virus Spreading Grow
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline plc is one of the first major pharma companies to announce plans to assess its current vaccine development platform in hope of starting research on a vaccine for Zika virus (ZIKV), following an outbreak of the disease in a number of countries.